Trial Outcomes & Findings for Blue Blockers at Night and Insomnia Symptoms (NCT NCT02698800)

NCT ID: NCT02698800

Last Updated: 2019-07-30

Results Overview

Pittsburgh Insomnia Rating Scale-65; measures the self-reported severity of insomnia over the past week. Higher scores indicate worsened severity. There are 65 items, each scored on a 4-point scale from low-high on symptom severity or frequency. There is a Total score, and 3 subscales: Distress score (how bothersome the sleep impairment is), Sleep Parameters score (sleep quality), and Quality of Life score. For the total score scoring is done by summing the scores from questions 1-65. Minimum Score=0 (good); Maximum Score=195 (bad) For the distress score, scoring is done by summing the scores from questions 1-46. Minimum Score=0 (not bothered); Maximum Score=138 (severely bothered) For the sleep parameters score, scoring is done by summing the scores from questions 47-56. Minimum Score=0 (good sleep); Maximum Score=30 (disrupted sleep) For the quality of life score, scoring is done by summing the scores from questions 57-65. Minimum Score=0 (excellent); Maximum Score=27 (poor)

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

15 participants

Primary outcome timeframe

After 7 nights of BB lenses

Results posted on

2019-07-30

Participant Flow

Participant milestones

Participant milestones
Measure
BB First (7 d), Then Clear (7 d), Separated by 4-wk Washout
Wearing of BB first for 7 days, followed by Clear lenses for 7 days, separated by 4-week washout period Blue blocking (BB) lenses: Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime. Clear lenses: Participants will wear clear lenses each night for 1 week for 2 hours preceding bedtime
Clear First (7 ), Then BB (7 d), Separated by 4-wk Washout
Wearing Clear lenses first for 7 days, followed by BB lenses for 7 days, separated by a 4-week washout period
Overall Study
STARTED
7
8
Overall Study
COMPLETED
6
8
Overall Study
NOT COMPLETED
1
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Blue Blockers at Night and Insomnia Symptoms

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Blue Blocking (BB)/Clear
n=14 Participants
Wearing of BB lenses. Blue blocking (BB) lenses: Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime. Clear lenses: Participants will wear clear lenses each night for 1 week for 2 hours preceding bedtime.
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
14 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Age, Continuous
46.6 years
STANDARD_DEVIATION 11.5 • n=5 Participants
Sex: Female, Male
Female
8 Participants
n=5 Participants
Sex: Female, Male
Male
6 Participants
n=5 Participants
Race/Ethnicity, Customized
Asian
2 Participants
n=5 Participants
Race/Ethnicity, Customized
Black/African American
6 Participants
n=5 Participants
Race/Ethnicity, Customized
White
6 Participants
n=5 Participants
Region of Enrollment
United States
14 participants
n=5 Participants

PRIMARY outcome

Timeframe: After 7 nights of BB lenses

Population: Participants who completed both phases

Pittsburgh Insomnia Rating Scale-65; measures the self-reported severity of insomnia over the past week. Higher scores indicate worsened severity. There are 65 items, each scored on a 4-point scale from low-high on symptom severity or frequency. There is a Total score, and 3 subscales: Distress score (how bothersome the sleep impairment is), Sleep Parameters score (sleep quality), and Quality of Life score. For the total score scoring is done by summing the scores from questions 1-65. Minimum Score=0 (good); Maximum Score=195 (bad) For the distress score, scoring is done by summing the scores from questions 1-46. Minimum Score=0 (not bothered); Maximum Score=138 (severely bothered) For the sleep parameters score, scoring is done by summing the scores from questions 47-56. Minimum Score=0 (good sleep); Maximum Score=30 (disrupted sleep) For the quality of life score, scoring is done by summing the scores from questions 57-65. Minimum Score=0 (excellent); Maximum Score=27 (poor)

Outcome measures

Outcome measures
Measure
Blue Blocking (BB)
n=14 Participants
Wearing of BB lenses. Blue blocking (BB) lenses: Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime.
Pittsburgh Insomnia Rating Scale-65 (PIRS65) Total Score
72.64 units on a scale
Standard Deviation 28.14

PRIMARY outcome

Timeframe: After 7 nights of clear lenses

Population: Participants who complete both phases

Pittsburgh Insomnia Rating Scale-65; measures the self-reported severity of insomnia over the past week. Higher scores indicate worsened severity. There are 65 items, each scored on a 4-point scale from low-high on symptom severity or frequency. There is a Total score, and 3 subscales: Distress score (how bothersome the sleep impairment is), Sleep Parameters score (sleep quality), and Quality of Life score. For the total score scoring is done by summing the scores from questions 1-65. Minimum Score=0 (good); Maximum Score=195 (bad) For the distress score, scoring is done by summing the scores from questions 1-46. Minimum Score=0 (not bothered); Maximum Score=138 (severely bothered) For the sleep parameters score, scoring is done by summing the scores from questions 47-56. Minimum Score=0 (good sleep); Maximum Score=30 (disrupted sleep) For the quality of life score, scoring is done by summing the scores from questions 57-65. Minimum Score=0 (excellent); Maximum Score=27 (poor)

Outcome measures

Outcome measures
Measure
Blue Blocking (BB)
n=14 Participants
Wearing of BB lenses. Blue blocking (BB) lenses: Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime.
Pittsburgh Insomnia Rating Scale-65 (PIRS65) Total Score
88.93 units on a scale
Standard Deviation 33.19

SECONDARY outcome

Timeframe: After 7 nights of BB lenses

Population: Participants who completed both phases

Wrist-worn accelerometry gives an estimate of time spent asleep, time spent in bed, and sleep efficiency can be calculated from this. Sleep efficiency is calculated as time spent asleep divided by total time in bed. Here, we considered the mean calculated sleep efficiency over each 7-day treatment period.

Outcome measures

Outcome measures
Measure
Blue Blocking (BB)
n=14 Participants
Wearing of BB lenses. Blue blocking (BB) lenses: Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime.
Sleep Efficiency (Time Spent Asleep Divided by Total Time in Bed) Determined With Wrist-worn Accelerometry
78.35 % of total sleep time
Standard Deviation 9

SECONDARY outcome

Timeframe: After 7 nights of clear lenses

Population: Participants who completed both phases

Wrist-worn accelerometry gives an estimate of time spent asleep, time spent in bed, and sleep efficiency can be calculated from this. Sleep efficiency is calculated as time spent asleep divided by total time in bed. Here, we considered the mean calculated sleep efficiency over each 7-day treatment period.

Outcome measures

Outcome measures
Measure
Blue Blocking (BB)
n=14 Participants
Wearing of BB lenses. Blue blocking (BB) lenses: Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime.
Sleep Efficiency (Time Spent Asleep Divided by Total Time in Bed) Determined With Wrist-worn Accelerometry
77.01 % of total sleep time
Standard Deviation 8.67

Adverse Events

Blue Blocking (BB)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Clear

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Ari Shechter, Principal Investigator

Columbia University Medical Center

Phone: 212-342-4487

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place